Acquired resistance to drugs targeting receptor tyrosine kinases
about
New and emerging factors in tumorigenesis: an overviewThe dynamic nature of the kinomeNewly discovered angiogenesis inhibitors and their mechanisms of actionNon-Darwinian dynamics in therapy-induced cancer drug resistance.Effects of the CK2 inhibitors CX-4945 and CX-5011 on drug-resistant cellsDisrupting the networks of cancerPlatelet-derived growth factor receptor/platelet-derived growth factor (PDGFR/PDGF) system is a prognostic and treatment response biomarker with multifarious therapeutic targets in cancers.MRI biomarkers identify the differential response of glioblastoma multiforme to anti-angiogenic therapy.Design and applications of bispecific heterodimers: molecular imaging and beyondTherapeutic modalities of squalenoyl nanocomposites in colon cancer: an ongoing search for improved efficacyReduced insulin-like growth factor I receptor and altered insulin receptor isoform mRNAs in normal mucosa predict colorectal adenoma risk.The war on cancer: lessons from the war on terrorMEK/ERK dependent activation of STAT1 mediates dasatinib-induced differentiation of acute myeloid leukemia.Lipid-Conjugation of Endogenous Neuropeptides: Improved Biotherapy against Human Pancreatic Cancer.PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical ModelsScreening of candidate G-quadruplex ligands for the human c-KIT promotorial region and their effects in multiple in-vitro models.Doxorubicin Differentially Induces Apoptosis, Expression of Mitochondrial Apoptosis-Related Genes, and Mitochondrial Potential in BCR-ABL1-Expressing Cells Sensitive and Resistant to Imatinib.Resistance to the nucleotide analogue cidofovir in HPV(+) cells: a multifactorial process involving UMP/CMP kinase 1ESR1 mutations—a mechanism for acquired endocrine resistance in breast cancer.CARP-1 functional mimetics are novel inhibitors of drug-resistant triple negative breast cancers.Kinase dysfunction and kinase inhibitors.Targeting tumor cell motility as a strategy against invasion and metastasis.Optimal management of Ewing sarcoma family of tumors: recent developments in systemic therapy.Identification of novel therapeutic target genes in acquired lapatinib-resistant breast cancer by integrative meta-analysis.Non-genetic cancer cell plasticity and therapy-induced stemness in tumour relapse: 'What does not kill me strengthens me'.Therapeutic drug monitoring of monoclonal antibodies in inflammatory and malignant disease: Translating TNF-α experience to oncology.KTN0158, a Humanized Anti-KIT Monoclonal Antibody, Demonstrates Biologic Activity against both Normal and Malignant Canine Mast Cells.Isolation and characterization of PDT-resistant cancer cells.Presence and utility of intrinsically disordered regions in kinases.EGFR mediates docetaxel resistance in human castration-resistant prostate cancer through the Akt-dependent expression of ABCB1 (MDR1).Expression of SLC22A1 variants may affect the response of hepatocellular carcinoma and cholangiocarcinoma to sorafenib.Canine osteosarcoma cells exhibit resistance to aurora kinase inhibitors.The future of cancer research: prevention, screening, vaccines, and tumor-specific drug combosPredictive simulation approach for designing cancer therapeutic regimens with novel biological mechanisms.Induction of multiple drug resistance in HMEC-1 endothelial cells after long-term exposure to sunitinib.The new era of nanotechnology, an alternative to change cancer treatment.A retrospective examination of the US Food and Drug Administration's clinical pharmacology reviews of oncology biologics for potential use of therapeutic drug monitoring.Autophagy inhibition improves the cytotoxic effects of receptor tyrosine kinase inhibitors.Cyclooxygenase inhibitors potentiate receptor tyrosine kinase therapies in bladder cancer cells in vitro.
P2860
Q26801253-0DAF9A7E-B167-4852-BCBE-2A543F01A93CQ26852588-1C9333B6-D373-4DAF-A838-549E1EAEEF0CQ26998498-F5F63E6D-9CED-43A5-8984-B6FB143D425BQ27324745-ABC5CAC7-F430-48DB-AD2A-62AAE0BFFC3DQ28485087-375117FA-5E4B-4180-91C6-749462605609Q28656016-611100D9-12DA-461E-8BA9-C9778097163EQ30250273-5E488570-E772-42B7-9CCA-4CF048B83F8CQ33616649-65F3D846-DA74-4590-BC1A-53B2DE65EC6BQ33732587-45B8027A-FF8E-474B-BEAA-14E1CCC19F41Q33765417-03B7A802-D44B-4424-9C5D-A682C5BA9047Q34361347-4BC61D77-132A-410D-8D7A-C40799124B99Q34368669-13E45FBF-C0B7-419A-A2A1-3DDFECFFF19AQ34794431-96FEA186-CE25-4846-81FC-CAE559411061Q35563739-808C4665-B5A0-46C6-93B5-AA5F08DC8E44Q35858617-4703889E-2034-4B21-8707-647E2C92E6B8Q35945953-C5518ADD-A6C2-4631-8D8C-5717CF6290E8Q36290275-49C64698-8A2A-46CB-BCFF-1B2608E41B1DQ36962978-B58D2095-65B9-4993-9F31-1F893FDFF59CQ37013898-36867006-A4D4-4624-A9F5-0E19A363A1B2Q37687393-4FA771CA-6E49-4133-8EEA-47F89CF5B757Q38075152-3E73A0D9-4FF0-4617-B636-A3DE278D3CA3Q38097602-2EA277D0-0D6A-489F-8648-33DEFFD823C4Q38113988-88D0A291-CBCB-4E3D-984A-AA9CFCA04921Q38457923-294BF045-5B9D-4429-8190-D6BF4E9E9EC7Q38474990-3B34CF38-92F1-4CBD-AD64-2375BBCCB4B5Q38564877-F05A9C7F-DEBD-4E0C-8E36-0E8B67D5A1C9Q38798420-F1A277B6-E377-4D0D-8B5A-48538DFDCAA6Q38903412-D81FBCA9-1282-4D0A-98E1-06E6AEF4E90CQ38968261-17CFD58D-D4A4-4B61-88CA-D89D0856C900Q38989173-703C8ECE-2369-4D1F-83BC-4D5564538650Q39175179-7B17B4A3-DBFB-45C3-8DCB-8BE2AAAB8C71Q39194457-1AFF3054-FD8E-477D-A5CB-816915266480Q39293011-2A18F427-F29E-499B-A151-FF48FB4102E8Q39765453-E788114E-3C16-4363-A7AF-1FA8F6F22A30Q41813347-B6FF265F-4F35-4637-9BC2-FA76686F7A46Q42370576-80DD61C2-3410-4CB5-8C69-1D098B6B6F6DQ49221285-F1AD0051-BC91-4B6C-BE66-F1DBB65E8E76Q54113343-EE07837C-4FC1-478C-A53C-17C04174FD1DQ55254546-8F310BB8-A78B-426B-903D-E3D16EE647B4
P2860
Acquired resistance to drugs targeting receptor tyrosine kinases
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Acquired resistance to drugs targeting receptor tyrosine kinases
@ast
Acquired resistance to drugs targeting receptor tyrosine kinases
@en
type
label
Acquired resistance to drugs targeting receptor tyrosine kinases
@ast
Acquired resistance to drugs targeting receptor tyrosine kinases
@en
prefLabel
Acquired resistance to drugs targeting receptor tyrosine kinases
@ast
Acquired resistance to drugs targeting receptor tyrosine kinases
@en
P2860
P1476
Acquired resistance to drugs targeting receptor tyrosine kinases
@en
P2093
Steven A Rosenzweig
P2860
P304
P356
10.1016/J.BCP.2011.12.025
P407
P577
2011-12-26T00:00:00Z